MUNICH (Reuters) - Eli Lilly's heart drug Effient failed to beat the older product Plavix in a head-to-head clinical study, dealing a blow to hopes for its expanded use in treating less critically sick heart patients who are managed solely with medicines.

haiti earthquake evacuation tax relief hurricane birmingham air ambulance
No comments:
Post a Comment